XML 28 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences Corporation Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2023     650.5          
Beginning balance at Dec. 31, 2023 $ 6,719.4 $ 6,650.0 $ 650.5 $ (5,024.5) $ 2,274.4 $ 8,992.4 $ (242.8) $ 69.4
Treasury stock, beginning balance (in shares) at Dec. 31, 2023       49.4        
Increase (Decrease) in Stockholders' Equity                
Net income 351.0 351.9       351.9   (0.9)
Other comprehensive (loss) gain, net of tax 9.5 9.5         9.5  
Common stock issued under stock plans (in shares)     1.3          
Common stock issued under stock plans 62.1 62.1 $ 1.3   60.8      
Stock-based compensation expense 44.6 44.6     44.6      
Purchases of treasury stock (0.2) (0.2)   $ (0.2)        
Common stock, ending balance (in shares) at Mar. 31, 2024     651.8          
Ending balance at Mar. 31, 2024 $ 7,186.4 7,117.9 $ 651.8 $ (5,024.7) 2,379.8 9,344.3 (233.3) 68.5
Treasury stock, ending balance (in shares) at Mar. 31, 2024       49.4        
Common stock, beginning balance (in shares) at Dec. 31, 2024 588.6   654.8          
Beginning balance at Dec. 31, 2024 $ 10,062.9 9,998.4 $ 654.8 $ (6,192.3) 2,613.4 13,167.0 (244.5) 64.5
Treasury stock, beginning balance (in shares) at Dec. 31, 2024 66.2     66.2        
Increase (Decrease) in Stockholders' Equity                
Net income $ 356.4 358.0       358.0   (1.6)
Other comprehensive (loss) gain, net of tax (10.0) (10.0)         (10.0)  
Common stock issued under stock plans (in shares)     1.1          
Common stock issued under stock plans 50.7 50.7 $ 1.1   49.6      
Stock-based compensation expense 40.2 40.2     40.2      
Purchases of treasury stock (in shares)       3.5        
Purchases of treasury stock $ (308.6) (308.6)   $ (258.6) (50.0)      
Common stock, ending balance (in shares) at Mar. 31, 2025 586.2   655.9          
Ending balance at Mar. 31, 2025 $ 10,191.6 $ 10,128.7 $ 655.9 $ (6,450.9) $ 2,653.2 $ 13,525.0 $ (254.5) $ 62.9
Treasury stock, ending balance (in shares) at Mar. 31, 2025 69.7     69.7